Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 study of Ad-RTS-hIL-12 plus veledimex in combination with Libtayo (cemiplimab-rwlc) in patients with rGBM

Trial Profile

A Phase 2 study of Ad-RTS-hIL-12 plus veledimex in combination with Libtayo (cemiplimab-rwlc) in patients with rGBM

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs Cemiplimab (Primary) ; INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Feb 2019 According to a ZIOPHARM Oncology media release, this trial is expected to begin in the second quarter of 2019.
    • 28 Nov 2018 New trial record
    • 12 Nov 2018 According to a ZIOPHARM Oncology media release, the company will initiate the trial in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top